Caszyme
Startup
Summarized by Halo AI
Caszyme is a Lithuanian biotechnology company that develops custom CRISPR-Cas gene-editing solutions. They utilize bioinformatics, AI, and protein engineering to discover and optimize novel enzymes for applications in therapeutics, agritech, and diagnostics.
Founded & HQ
Vilnius, Lithuania
Company size
11-50 employees
IP status
7 grants confirmed
Activity highlights
Partnered with Integra Therapeutics and awarded a 1 million euro Eurostars grant to develop version 2.0 of the FiCAT gene-writing platform.
Caszyme is a biotech company founded in 2017 in Vilnius, Lithuania, focused on developing and applying CRISPR gene editing technologies. They partner with industry leaders to create innovative solutions for healthcare and sustainability challenges.
AI summary generated on Jun 22, 2026
OpenAlex
OpenAlexFor general inquiries
MP
Monika Paule
CEO
Is this page yours? Boost its visibility
List technologies, facilities, services, or grant collaboration opportunities.
Partner smarter. Move faster.
Get new partnering requests
delivered to your inbox.
delivered to your inbox.
© 2026 Halo Cures, Inc.